Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:50-300,IF 1:50-200
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 %BSA
Konservierungsmittel
ProClin
Vorsichtsmaßnahmen
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
AKAP9
(A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))
Andere Bezeichnung
AKAP9
Hintergrund
A-kinase anchor protein 9, AKAP-9, A-kinase anchor protein 350 kDa, AKAP 350, hgAKAP 350, A-kinase anchor protein 450 kDa, AKAP 450, AKAP 120-like protein, Centrosome- and Golgi-localized PKN-associated protein, CG-NAP, Protein hyperio, Protein kinase A-anchoring protein 9, PRKA9, Protein yotiaoAKAP9 encodes a member of the AKAP family. Alternate splicing of AKAP9 results in at least two isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon and phosphodiesterase 4D3.